Abstracts

NADIR CD4 AND ANAL CYTOLOGY PREDICT DEVELOPMENT OF INVASIVE ANAL CANCER

Background: The long-term natural history of anal high-grade squamous intraepithelial lesions (HSIL) is incompletely characterized. We aimed to evaluate the effects of readily available patient characteristics on the risk of developing IAC in a longitudinal cohort of people with HIV (PWH) Methods: Retrospective inception cohort analysis of PWH between 2006-2021. Patients were eligible if they…

GLYCOENGINEERING ENHANCES HIV 10-1074 bNAb-DEPENDENT NATURAL KILLER CELL CYTOTOXICITY

Background: Broadly neutralizing antibodies (bNAbs) are being clinically tested to cure HIV. Such bNAbs are recognized for their potent neutralizing activity. However, beyond neutralization, the constant domains (Fc) of antibodies can elicit several innate immune functions, such as antibody-dependent cellular cytotoxicity by natural killer (NK) cells (ADCC). Antibody Fc glycosylation impacts these functions; however, whether…

LOWER ACADEMIC PERFORMANCE AMONG CHILDREN WITH PERINATAL HIV EXPOSURE IN BOTSWANA

Background: Higher risk of suboptimal neurodevelopment has been identified among children who are HIV-exposed but uninfected (HEU) compared to children born to women without HIV in some studies. However, academic performance of school-aged children by HIV exposure status has not been well studied. Methods: The Botswana-based FLOURISH study is an ongoing prospective observational study re-enrolling…

POST-ACUTE COVID OUTCOMES: AMUBARVIMAB/ROMLUSEVIMAB VS PLACEBO IN THE ACTIV-2 TRIAL

Background: Whether early antiviral therapy reduces the risk of Long COVID is not known. The combination SARS-CoV-2 monoclonal antibodies amubarvimab+romlusevimab (A+R) were highly effective in reducing 28-day all-cause hospitalization/death among high-risk adults with mild-to-moderate COVID-19 in the randomized, placebo-controlled ACTIV-2/A5401 trial. We assessed the impact of A+R on late outcomes including Long COVID in ACTIV-2.…